At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 881 enrolled
Drug / intervention
Troriluzole +1 moredrug
Likely dose
Troriluzole 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder
In Brief
A Phase 3 clinical trial evaluating Troriluzole and Placebo for Generalized Anxiety Disorder. Completed, enrolled 881 participants across 53 sites.
Detailed Summary
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionJan 2020
Study CompletionMay 2020
TodayJul 2026
First PostedFeb 4, 2019
Enrollment StartFeb 19, 2019
Primary CompletionJan 14, 2020
Study CompletionMay 8, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.4 years ago
Interventions
Troriluzoledrug
100 mg capsule
Placebodrug
Placebo matched to troriluzole